Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

634
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
634
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

887
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
887
Preventive Healthcare Services01:30

Preventive Healthcare Services

2.2K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.2K
Levels of Health Promotion and Illness Prevention01:26

Levels of Health Promotion and Illness Prevention

12.5K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
12.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

442
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction.

Pharmacy (Basel, Switzerland)·2022
Same author

Association of Low-Density Lipoprotein Cholesterol Levels with More than 20-Year Risk of Cardiovascular and All-Cause Mortality in the General Population.

Journal of the American Heart Association·2022
Same author

Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning.

Journal of biomedical informatics·2022
Same author

Trans Fatty Acid Biomarkers and Incident Type 2 Diabetes: Pooled Analysis of 12 Prospective Cohort Studies in the Fatty Acids and Outcomes Research Consortium (FORCE).

Diabetes care·2022
Same author

Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.

JAMA network open·2022
Same author

Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012).

Journal of thrombosis and thrombolysis·2021

Related Experiment Video

Updated: Apr 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Starting primary prevention earlier with statins.

Jennifer G Robinson1

  • 1Department of Epidemiology, University of Iowa, Iowa City, Iowa; Department of Medicine, University of Iowa, Iowa City, Iowa; Prevention Intervention Center, College of Public Health, University of Iowa, Iowa City, Iowa.

The American Journal of Cardiology
|September 11, 2014
PubMed
Summary
This summary is machine-generated.

Earlier statin therapy initiation is recommended for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults. Evidence supports statins for those with ≥7.5% 10-year ASCVD risk, with consideration for lower-risk groups.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K

Related Experiment Videos

Last Updated: Apr 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • The 2013 ACC/AHA guideline on cholesterol treatment recommends statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) based on risk stratification.
  • Evidence suggests statin therapy benefits outweigh risks for individuals with ≥7.5% 10-year ASCVD risk.

Purpose of the Study:

  • To evaluate the evidence supporting earlier statin therapy initiation for primary prevention of ASCVD.
  • To assess the impact of statins on mortality and atherosclerosis progression.

Main Methods:

  • Systematic review of randomized trials with ASCVD outcomes and meta-analyses published through 2011.
  • Analysis of subsequent meta-analyses, imaging trials, and epidemiologic studies.

Main Results:

  • Statin therapy is recommended for primary prevention in adults with ≥7.5% 10-year ASCVD risk and considered for those with 5% to <7.5% risk.
  • Meta-analyses support these recommendations and show reduced total mortality in lower-risk subjects.
  • Earlier statin initiation may more effectively prevent age-related atherosclerosis progression.

Conclusions:

  • Earlier intervention with statin therapy is strongly supported by current evidence for primary ASCVD prevention.
  • Initiating statin therapy earlier has the potential for significant long-term impact on cardiovascular disease burden in aging populations.
  • The safety, availability, and low cost of generic statins further support earlier intervention.